Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CYNO's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

CYNO Guru Trades in Q2 2016

Jim Simons 270,571 sh (New)
Jim Chanos 73,367 sh (New)
Paul Tudor Jones 7,500 sh (+48.46%)
Mario Gabelli 10,581 sh (unchged)
Ken Fisher 96,170 sh (-15.80%)
Steven Cohen 439,900 sh (-17.84%)
Robert Olstein 30,375 sh (-38.76%)
Joel Greenblatt 30,088 sh (-48.63%)
» More
Q3 2016

CYNO Guru Trades in Q3 2016

Steven Cohen Sold Out
Jim Chanos Sold Out
Robert Olstein 29,875 sh (-1.65%)
Mario Gabelli 9,581 sh (-9.45%)
Jim Simons 229,571 sh (-15.15%)
Ken Fisher 73,253 sh (-23.83%)
Paul Tudor Jones 5,152 sh (-31.31%)
Joel Greenblatt 19,134 sh (-36.41%)
» More
Q4 2016

CYNO Guru Trades in Q4 2016

Jeremy Grantham 50,000 sh (New)
Paul Tudor Jones 6,300 sh (+22.28%)
Robert Olstein 35,525 sh (+18.91%)
Mario Gabelli 9,581 sh (unchged)
Jim Simons Sold Out
Joel Greenblatt Sold Out
Ken Fisher 38,635 sh (-47.26%)
» More
Q1 2017

CYNO Guru Trades in Q1 2017

Robert Olstein Sold Out
Jeremy Grantham Sold Out
Mario Gabelli Sold Out
Paul Tudor Jones Sold Out
Ken Fisher Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CYNO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:HKSE:00853, SHSE:603387, SZSE:002317, SHSE:603579, SZSE:300298, XTAE:MZOR, NYSE:ITGR, TSE:3360, NAS:AXGN, TSE:7817, NAS:CNMD, HKSE:01302, OCSE:OSSR, XTER:DRW3, SZSE:300273, XSWX:YPSN, NAS:XENT, SZSE:300326, NAS:OFIX, NAS:BABY » details
Traded in other countries:C9S.Germany,
Headquarter Location:USA
Cynosure Inc develops & markets aesthetic treatment systems that enable plastic surgeons, dermatologists & other medical practitioners to perform non-invasive & minimally invasive procedures to remove hair, treat vascular & benign pigmented lesion, etc.

Cynosure Inc was incorporated in July 1991. The Company develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus and ablate sweat glands. It has also developed an aesthetic treatment product for the home use market. The Company sells its products through a direct sales force in North America, France, Spain, the United Kingdom, Germany, Australia, Korea, China, Japan and Mexico and through international distributors in approximately 120 other countries. Its product portfolio is composed of various energy sources including Alexandrite, diode, Nd:YAG, picosecond, pulse dye, and Q-switched lasers and intense pulsed light. It offers single energy source systems as well as workstations that incorporate two or more different types of lasers or pulsed light technologies. It offers multiple technologies and system alternatives at various price points depending mainly on the number and type of energy sources included in the system. Its products are designed to be easily upgradeable to add additional energy sources and handpieces, which provide its customers with technological flexibility as it expand their practices. The Company's latest innovations are SmartLipo system and PicoSure system. The Company's flagship products include Elite, Affirm/SmartSkin, Cynergy, Accolade. The Company sells its aesthetic treatment systems to the traditional physician customer base of dermatologists and plastic surgeons as well as to non-traditional physician customers who are providing aesthetic services using laser and light-based technology. Non-traditional physician customers can include primary care physicians, obstetricians and gynecologists. As of December 31, 2013, the Company owns over 60 United States patents, as well as many United States pending applications and foreign patents and pending applications. It is also joint owners with El.En. of certain patents and pending applications. The Company competes with Cutera, Solta Medical, Syneron Medical, ZELTIQ Aesthetics, Alma Lasers among others. Its products are medical devices subject to extensive and rigorous regulation by the U.S. Food and Drug Administration, or FDA, as well as other regulatory bodies.

Top Ranked Articles about Cynosure Inc

Small Caps: Assessing Management Guidance and Analysts’ Estimates Plus, positive and negative fundamentals to watch
In the short term, stock prices may be driven by the events of the day, chaotic as they may be. But, in the long term, it’s all about the fundamentals, particularly growth in earnings — or lack thereof. Read more...

Ratios

vs
industry
vs
history

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue (TTM) (Mil) $433.53
EPS (TTM) $ 0.59
52-Week Range $39.90 - 66.65
Shares Outstanding (Mil)24.10

Analyst Estimate

Dec17
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) 1.58
EPS without NRI ($) 1.58
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}